Vorapaxar: First global approval

Drugs

Volumn 74, Issue 10, 2014, Pages 1153-1163

  Poole, Raewyn M ^a   Elkinson, Shelley ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; CARBAMAZEPINE; CLARITHROMYCIN; CONIVAPTAN; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; NELFINAVIR; PHENYTOIN; POSACONAZOLE; RITONAVIR; SAQUINAVIR; TELAPREVIR; TELITHROMYCIN; VORAPAXAR; ANTITHROMBOCYTIC AGENT; LACTONE; PROTEINASE ACTIVATED RECEPTOR 1; PYRIDINE DERIVATIVE;

ANEMIA; ARTERIAL THROMBOEMBOLISM; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; DEPRESSION; DIPLOPIA; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; KIDNEY DISEASE; MAXIMUM PLASMA CONCENTRATION; MODERATE HEPATIC IMPAIRMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); QT INTERVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; ANTAGONISTS AND INHIBITORS; CHEMISTRY; MYOCARDIAL INFARCTION; PERIPHERAL ARTERIAL DISEASE;

DRUG APPROVAL; HUMANS; LACTONES; MYOCARDIAL INFARCTION; PERIPHERAL ARTERIAL DISEASE; PLATELET AGGREGATION INHIBITORS; PYRIDINES; RECEPTOR, PAR-1;

EID: 84903907201     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-014-0252-2     Document Type: Article

References (50)

1. Steg PG, Dorman SH, Amarenco P. Atherothrombosis and the role of antiplatelet therapy. J Thromb Haemost. 2011;9(Suppl 1):325-32.
2. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124(22):2458- 73.
3. Anderson JL, Adams CD, Antman EM, et al. 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;123(18):e426-579.
4. Leonardi S, Tricoci P, Becker RC. Thrombin receptor antagonists for the treatment of atherothrombosis: therapeutic potential of vorapaxar and E-5555. Drugs. 2010;70(14):1771-83.
5. Angiolillo DJ. The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Drugs. 2012;72:2087-116.
6. Cho JR, Rollini F, Franchi F, et al. Unmet needs in the management of acute myocardial infarction: Role of novel protease-activated receptor-1 antagonist vorapaxar. Vasc Health Risk Manag. 2014;10:177-88.
7. Gurbel PA, Jeong Y-H, Tantry US. Vorapaxar: a novel protease-activated receptor-1 inhibitor. Expert Opin Investig Drugs. 2011;20(10):1445-53.
8. FDA. FDA approves Zontivity to reduce the risk of heart attacks and stroke in highrisk patients. http://www.fdagov/NewsEvents/Newsroom/ PressAnnouncements/ucm396585htm. 2014.
9. Prescribing information. http://www.merckcom/product/usa/pi-circulars/z/ zontivity/zontivity-pipdf. 2014.
10. Merck. Merck Statement on Changes to Clinical Studies of Vorapaxar. Media Release. 2011.
11. Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012;366(15):1404-13.
12. European Medicines Agency. Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use, January 2014.
13. Merck. New Merck Begins Operations. Media Release. 2009.
14. Kosoglou T, Reyderman L, Kasserra C, et al. Optimizing dose of the novel thrombin receptor antagonist SCH 530348 based on pharmacodynamics and pharmacokinetics in healthy subjects. Clin Pharmacol Ther. 2008;83(Suppl. 1):55.
15. Kosoglou T, Reyderman L, Tiessen RG, et al. Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects. Eur J Clin Pharmacol. 2012;68(3):249-58.
16. Storey RF, Kotha J, Smyth S, et al. Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy. Thromb Haemost. 2014;111(5):883-91.
17. Kosoglou T, Hunt TL, Xuan F, et al. Effect of the thrombin receptor antagonist (PAR-1) vorapaxar on QT/QTc interval in healthy volunteers: A randomized, placebo- and positive-controlled, parallel group trial. Clin Pharmacol Drug Dev. 2014;3(1):18-24.
18. Ghosal A, Lu X, Penner N, et al. Identification of human liver cytochrome P450 enzymes involved in the metabolism of SCH 530348 (Vorapaxar), a potent oral thrombin protease-activated receptor 1 antagonist. Drug Metab Dispos. 2011;39(1):30-8.
19. Kosoglou T, Reyderman L, Tseng J, et al. Effect of food, antacid, and age on the pharmacokinetics of the oral thrombin receptor antagonist vorapaxar (sch 530348) in healthy volunteers. Clin Pharmacol Drug Dev. 2013;2(3):223-30.
20. Behm MO, Kosoglou T, Miltenburg AMM, et al. The absence of a clinically significant effect of food on the single dose pharmacokinetics of Vorapaxar, a PAR-1 antagonist, in healthy adult subjects. Clin Pharmacol Drug Dev. 2013;2(4):310-5.
21. Kosoglou T, Reyderman L, Kasserra C, et al. No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects. Eur J Clin Pharmacol. 2012;68(3):291-300.
22. Statkevich P, Kosoglou T, Kumar B, et al. Pharmacokinetics of vorapaxar and its metabolite sch 2046273 (M20) following oral administration in healthy chinese and us subjects. Clin Pharmacol Ther. 2012;91:S54.
23. Statkevich P, Kosoglou T, Preston RA, et al. Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment. Eur J Clin Pharmacol. 2012;68(11):1501-8.
24. Kosoglou T, Kraft WK, Kumar B, et al. Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease. Eur J Clin Pharmacol. 2012;68(7):1049-56.
25. Kosoglou T, Statkevich P, Kumar B, et al. The effect of multiple doses of ketoconazole or rifampin on the single- and multiple-dose pharmacokinetics of vorapaxar. J Clin Pharmacol. 2013;53(5):540-9.
26. Kosoglou T, Zhu Y, Xuan F, et al. Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin. Eur J Clin Pharmacol. 2012;68(11):1509-16.
27. Kosoglou T, Zhu Y, Statkevich P, et al. The influence of multiple-dose vorapaxar, an oral PAR-1 receptor antagonist, on the single-dose pharmacokinetics and pharmacodynamics of digoxin. Clin Pharmacol Drug Dev. 2013;2(1):90-8.
28. Bohula May EA, Bonaca MP, Scirica BM, et al. Rates of arterial revascularization in patients treated with vorapaxar vs. Placebo in the TRA 2degreeP-TIMI 50 trial. Circulation. 2012;126(21 SUPPL. 1):A19221.
29. Bonaca MP, Scirica BM, Braunwald E, et al. Efficacy of vorapaxar is not modified by thienopyridine therapy: Results from TRA 2degreeP-TIMI 50 trial. Circulation. 2012;126(21 SUPPL. 1):A18595.
30. Scirica BM, Bonaca MP, Braunwald E, et al. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2degreeP-TIMI 50 trial. Lancet. 2012;380(9850):1317-24.
31. Scirica BM, Bonaca MP, Braunwal E, et al. Vorapaxar for secondary prevention after myocardial infarction according to aspirin dose-insights from the TRA2degreep-timi 50 trial. Circulation. 2012;126(21 SUPPL. 1):A14508.
32. Cavender MA, Scirica B, Bonaca MP, et al. Vorapaxar in patients with diabetes and prior MI: Findings from the TRA 2p-TIMI 50 trial. [abstract no. 10398]. In: American Heart Association Scientific Sessions; 16-20 Nov 2013; Dallas, TX.
33. Morrow DA, Alberts MJ, Mohr JP, et al. Efficacy and safety of vorapaxar in patients with prior ischemic stroke. Stroke. 2013;44(3):691-8.
34. Bonaca MP, Scirica BM, Creager MA, et al. Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50. Circulation. 2013;127(14):1522-9, 9e1-6.
35. Bonaca MP, Scirica BM, Braunwald E, et al. Vorapaxar reduces coronary stent thrombosis: Results from the TRA2P-TIMI 50 trial. Circulation. 2013;128(22 SUPPL. 1):A18928.
36. Bonaca MP, Scirica BM, Braunwald E, et al. New ischemic stroke and outcomes with vorapaxar vs. Placebo: Results from TRA 2degreeP-TIMI 50 trial. Circulation. 2012;126(21 SUPPL. 1):A19144.
37. Tricoci P, Huang Z, Held C, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 2012;366(1):20-33.
38. Armaganijan L, Lopes R, Huang Z, et al. Efficacy and safety of vorapaxar in elderly patients with non-st-segment elevation acute coronary syndrome: Insights from the tracer trial. Circulation Conference: American Heart Association. 2013;128(22 SUPPL. 1).
39. Jones S, Tricoci P, Huang Z, et al. Vorapaxar in non-ST-segment elevation acute coronary syndrome patients with peripheral artery disease: Results from tracer. [abstract no. 17939]. In: American Heart Association Scientific Sessions; 16-20 Nov 2013; Dallas, TX.
40. Mahaffey KW, Huang Z, Wallentin L, et al. Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial). Am J Cardiol. 2014;113(6):936-44.
41. Cornel JH, Tricoci P, Horton J, et al. Effects of glycoprotein IIB/IIIA inhibitors in combination with vorapaxar, a platelet thrombin-receptor antagonist, among patients with non-St-segment elevation acute coronary syndromes: Insights from the tracer trial. J Am Coll Cardiol. 2013;(1):E102.
42. Tricoci P, Chen E, Neely ML, et al. CYP2C19 polymorphism and pon-1 activity in NSTE acs: Vorapaxar effect in relation to clopidogrel metabolism in the tracer trial. [abstract no. 17658]. In: American Heart Association Scientific Sessions; 16-20 Nov 2013; Dallas, TX.
43. Leonardi S, Tricoci P, White HD, et al. Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRACER) trial. Eur Heart J. 2013;34(23):1723-31.
44. Tricoci P, Huang Z, Van De Werf F, et al. Net clinical benefit of vorapaxar in NSTE ACS: Role of ischemic and bleeding risk stratification. Circulation. 2012;126(21 SUPPL. 1):A19049.
45. Held C, Tricoci P, Huang Z, et al. Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-st-segment elevation acute coronary syndrome: Results from the TRACER Trial. Circulation. 2012;126(21 SUPPL. 1):A9964.
46. Valgimigli M, Tricoci P, Huang Z, et al. Vorapaxar, a platelet thrombin-receptor antagonist, in patients with non-st-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: Results from the tracer trial. Circulation. 2012;126(21 SUPPL. 1):A18805.
47. Whellan DJ, Tricoci P, Chen E, et al. Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome). J Am Coll Cardiol. 2014;63(11):1048-57.
48. Becker RC, Moliterno DJ, Jennings LK, et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo- controlled phase II study. Lancet. 2009;373:919-28.
49. Goto S, Yamaguchi T, Ikeda Y, et al. Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome. J Atheroscler Thromb. 2010;17(2):156-64.
50. Tricoci P, Huang Z, White HD, et al. Clinical characteristics associated with major bleeding in NSTE ACS and the relationship between bleeding risk, ischemic events, and the vorapaxar effect: analysis from the TRACER trial. Eur Heart J. 2012;33:322.